Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | CCR1 | P32246 | 2/20 | 0.37 |
| ▸ | CCR5 | P51681 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | METAP2 | P50579 | 1/20 | 0.32 |
| ▸ | CASP6 | P55212 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29652865 | 1.00 | RAB9A (0.37) | RAB9ACCR1CCR5CYP1A2KDM4E | |
| SCHEMBL426850 | 0.79 | — | — | |
| Water SCHEMBL29954949 | 0.77 | — | — | |
| SCHEMBL29952049 | 0.77 | — | — | |
| Water SCHEMBL1669028 | 0.77 | — | — | |
| SCHEMBL30788696 | 0.76 | CCR1 (0.40) | RAB9ACCR1CCR5CYP1A2KDM4E | |
| SCHEMBL489376 | 0.76 | CCR1 (0.40) | RAB9ACCR1CCR5CYP1A2KDM4E | |
| SCHEMBL29953898 | 0.76 | BACE1 (0.39) | RAB9AKDM4ELMNANPC1TP53 | |
| SCHEMBL29957469 | 0.76 | ENPP2 (0.30) | — | |
| SCHEMBL13725857 | 0.76 | ENPP2 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260047267-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2026-02-12 | — | — | US | disclosed |
| US-12116369-B2 | Substituted pyrazolo[1,5-a]pyrimidines as glucocerebrosidase activators | Bial—R&D Investments, S.A. (PT) | 2024-10-15 | — | — | US | disclosed |
| CN-118359538-A | Isoquinoline compound, preparation method, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2024-07-19 | — | — | CN | disclosed |
| US-20230098494-A1 | PYRAZOLO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | LYSOSOMAL THERAPEUTICS INC. | 2023-03-30 | — | — | US | disclosed |
| EP-3752512-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2023-03-01 | — | — | EP | disclosed |
| US-11529356-B2 | 2-(morpholin-4-yl)-1,7-naphthyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-12-20 | — | — | US | disclosed |
| CN-109311887-B | Pyrazolo [1,5-a ] pyrimidinecarboxamide compounds and their use in the treatment of medical conditions | BIAL研发投资股份有限公司 | 2022-09-13 | — | — | CN | disclosed |
| WO-2022109492-A1 | PYRROLOPYRIDAZINE COMPOUNDS AS KINASE INHIBITORS | GOSSAMER BIOSERVICES, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| CN-110204544-B | 2- (morpholin-4-yl) -1, 7-naphthyridine | 拜耳制药股份公司 | 2022-04-12 | — | — | CN | disclosed |
| US-20220098477-A1 | MONONUCLEAR IRIDIUM COMPLEXES CONTAINING THREE ORTHO-METALLATED BIDENTATE LIGANDS AND OPTICAL ORIENTATING ANISTROPHY | UDC IRELAND LIMITED (IE) | 2022-03-31 | — | — | US | disclosed |
| WO-2008070692-A2 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | WO | disclosed |
| US-20080076924-A1 | Piperazines as P2X7 antagonists | ABBOTT LABORATORIES | 2008-03-27 | — | — | US | disclosed |
| US-20080076924-A1 | Piperazines as P2X7 antagonists | ABBOTT LABORATORIES | 2008-03-27 | — | — | US | disclosed |
| WO-2008001076-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2008-01-03 | — | — | WO | disclosed |
| US-20070249642-A1 | Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione | GLAXO GROUP LIMITED (GB) | 2007-10-25 | — | — | US | disclosed |
| WO-2007113232-A1 | AZABICYCLO [3. 1. 0] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007073283-A1 | SUBSTITUTED CINNOLINE DERIVATIVES AS GABAA-RECEPTOR MODULATORS AND METHOD FOR THEIR SYNTHESIS | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
| US-20070142382-A1 | Compounds and Uses Thereof | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | US | disclosed |
| US-20070142328-A1 | Compounds and Uses Thereof | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | US | disclosed |
| US-20060122256-A1 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activators | GILLESPIE PAUL | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12116369-B2 | Substituted pyrazolo[1,5-a]pyrimidines as glucocerebrosidase activators | GBA1, GALC, GBA3 | RAB9A 806/4885CCR1 3463/4885CCR5 2120/4885 |
| US-20070142328-A1 | Compounds and Uses Thereof | MAPT, BDNF, PYGB | RAB9A 1318/4885CCR1 4575/4885CCR5 4750/4885 |
| US-20230098494-A1 | PYRAZOLO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GAA, PARK7 | RAB9A 1599/4885CCR1 3077/4885CCR5 1784/4885 |
| US-20060122256-A1 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activators | GYS2, GYS1, GSK3A | RAB9A 4301/4885CCR1 2838/4885CCR5 4180/4885 |
| US-20070142382-A1 | Compounds and Uses Thereof | MAPT, BDNF, PYGB | RAB9A 1318/4885CCR1 4575/4885CCR5 4750/4885 |
| US-11529356-B2 | 2-(morpholin-4-yl)-1,7-naphthyridines | POLQ, CCND2, NRAS | RAB9A 1025/4885CCR1 4302/4885CCR5 3363/4885 |
| US-20220098477-A1 | MONONUCLEAR IRIDIUM COMPLEXES CONTAINING THREE ORTHO-METALLATED BIDENTATE LIGANDS AND OPTICAL ORIENTATING ANISTROPHY | ICOSLG, CCL11, CCR3 | RAB9A 2207/4885CCR1 33/4885CCR5 18/4885 |
| US-20070249642-A1 | Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione | AZI2, NT5C3B, CYP1B1 | RAB9A 715/4885CCR1 1890/4885CCR5 334/4885 |
| US-20080076924-A1 | Piperazines as P2X7 antagonists | P2RX7, P2RX1, P2RX2 | RAB9A 3303/4885CCR1 932/4885CCR5 458/4885 |
| US-20260047267-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | LBR, OXER1, NPY1R | RAB9A 1020/4885CCR1 85/4885CCR5 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.